1.Constructing a model of degenerative scoliosis using finite element method:biomechanical analysis in etiology and treatment
Kai HE ; Wenhua XING ; Shengxiang LIU ; Xianming BAI ; Chen ZHOU ; Xu GAO ; Yu QIAO ; Qiang HE ; Zhiyu GAO ; Zhen GUO ; Aruhan BAO ; Chade LI
Chinese Journal of Tissue Engineering Research 2025;29(3):572-578
BACKGROUND:Degenerative scoliosis is defined as a condition that occurs in adulthood with a coronal cobb angle of the spine>10° accompanied by sagittal deformity and rotational subluxation,which often produces symptoms of spinal cord and nerve compression,such as lumbar pain,lower limb pain,numbness,weakness,and neurogenic claudication.The finite element method is a mechanical analysis technique for computer modelling,which can be used for spinal mechanics research by building digital models that can realistically restore the human spine model and design modifications. OBJECTIVE:To review the application of finite element method in the etiology and treatment of degenerative scoliosis. METHODS:The literature databases CNKI,PubMed,and Web of Science were searched for articles on the application of finite element method in degenerative scoliosis published before October 2023.Search terms were"finite element analysis,biomechanics,stress analysis,degenerative scoliosis,adult spinal deformity"in Chinese and English.Fifty-four papers were finally included. RESULTS AND CONCLUSION:(1)The biomechanical findings from the degenerative scoliosis model constructed using the finite element method were identical to those from the in vivo experimental studies,which proves that the finite element method has a high practical value in degenerative scoliosis.(2)The study of the etiology and treatment of degenerative scoliosis by the finite element method is conducive to the prevention of the occurrence of the scoliosis,slowing down the progress of the scoliosis,the development of a more appropriate treatment plan,the reduction of complications,and the promotion of the patients'surgical operation.(3)The finite element method has gradually evolved from a single bony structure to the inclusion of soft tissues such as muscle ligaments,and the small sample content is increasingly unable to meet the research needs.(4)The finite element method has much room for exploration in degenerative scoliosis.
2.Construction and validation of a prediction model for UGIB in patients receiving dual antiplatelet therapy after PCI
Jingyi YANG ; Bing PAN ; Shengxiang FENG ; Jiexin MING ; Hongwei YU
Chinese Journal of Geriatric Heart Brain and Vessel Diseases 2025;27(5):596-600
Objective To explore the risk factors for UGIB after dual antiplatelet therapy(aspirin+P2Y12 receptor antagonist)in elderly patients with acute coronary syndrome(ACS)undergoing PCI,and then construct a nomogram model.Methods A total of 1590 elderly patients diagnosed with ACS and then undergoing PCI in Jinzhou Central Hospital from January 2019 to June 2022 were retrospectively recruited,and randomly divided into a testing group(n=1114)and a valida-tion group(n=476)in a ratio of 7∶3.Univariate and multivariate logistic regression analyses were applied to identify the independent risk factors for UGIB events,and then a prediction model was constructed and verified for its diagnostic performance.The predictive value of our prediction model for UGIB events was compared with that of PRECISE-DAPT scoring system.Results There were no statistical differences in baseline data between the testing group and the validation group(P>0.05).The incidence of UGIB was 3.9%(62/1590)in the patients.Multivariate logistic regression analysis indicated that age(OR=1.064,95%CI:1.032-1.097,P=0.000),alcohol(OR=2.433,95%CI:1.220-4.823,P=0.011),heart failure(OR=3.734,95%CI:1.882-7.404,P=0.000),gastrointestinal ulcer/bleeding(OR=3.030,95%CI:1.391-6.618,P=0.005),and Cr(OR=1.017,95%CI:1.014-1.040,P=0.000)were independent risk factors for UGIB in these patients after dual antiplatelet therapy.The constructed nomogram model based on the risk factors obtained an AUC value of 0.806(95%CI:0.739-0.872)in the testing set and 0.838(95%CI:0.737-0.945)in the validation set.The AUC value of the PRECISE-DAPT scoring system in predicting UGIB was 0.674(95%CI:0.583-0.766),which was significantly lower than our mod-el(P<0.05),indicating the nonogram showing good discriminability.Calibration curve analysis and H-L goodness of fit test revealed that our model had good consistency and was well fit(vali-dation set:P=0.846,testing set:P=0.326).Decision curve analysis displayed that our model showed good potential clinical benefits.Conclusion Age,history of gastrointestinal ulcer/bleed-ing,alcohol,heart failure and Cr are independent risk factors for UGIB in these post-PCI patients after dual antiplatelet therapy.The prediction model constructed with these factors has good dis-criminability,calibration and fitting,shows sound clinical application,and can be served as an ef-fective prediction tool for UGIB events in the patients.
3.Adjuvant Targeted Therapy for Stage IB EGFR-Mutant NSCLC: Advances and Perspectives
Yu LIU ; Shengxiang REN ; Gening JIANG
Chinese Journal of Thoracic and Cardiovascular Surgery 2025;41(8):508-512
Stage ⅠB non-small cell lung cancer (NSCLC), a potentially curable malignancy, continues to exhibit a substantial recurrence rate post-surgery. Targeted therapy has significantly improved the prognosis of patients with advanced epidermal growth factor receptor mutation (EGFRm), while the need and optimal timing for adjuvant targeted therapy in epidermal growth factor receptor mutant (EGFRm) stage ⅠB patients remain unclear. This review systematically examines the advancements of adjuvant targeted therapy in stage ⅠB EGFRm NSCLC and critically explores the practical problems in its clinical application. Third-generation targeted agents, such as Osimertinib, have significantly improved disease-free survival in stage ⅠB EGFRm NSCLC according to the seventh edition of the TNM staging system. However, the survival benefits in this population based on the eighth/ninth edition staging systems have yet to be fully validated, and stage ⅠB NSCLC patients exhibit different treatment response patterns. Consequently, current research focuses on high-risk subgroups to optimize treatment outcomes. Major clinical challenges include acquired resistance, determining the optimal treatment timing, and implementing individualized treatment strategies. Future research should concentrate on elucidating the mechanisms of resistance, optimizing treatment timing, establishing precise risk stratification systems, and exploring personalized treatment strategies guided by dynamic monitoring of circulating tumor DNA. This review aims to provide a comprehensive analysis of these key issues and offer a theoretical foundation for optimizing the clinical practice of adjuvant targeted therapy in stage ⅠB NSCLC.
4.Adjuvant Targeted Therapy for Stage IB EGFR-Mutant NSCLC: Advances and Perspectives
Yu LIU ; Shengxiang REN ; Gening JIANG
Chinese Journal of Thoracic and Cardiovascular Surgery 2025;41(8):508-512
Stage ⅠB non-small cell lung cancer (NSCLC), a potentially curable malignancy, continues to exhibit a substantial recurrence rate post-surgery. Targeted therapy has significantly improved the prognosis of patients with advanced epidermal growth factor receptor mutation (EGFRm), while the need and optimal timing for adjuvant targeted therapy in epidermal growth factor receptor mutant (EGFRm) stage ⅠB patients remain unclear. This review systematically examines the advancements of adjuvant targeted therapy in stage ⅠB EGFRm NSCLC and critically explores the practical problems in its clinical application. Third-generation targeted agents, such as Osimertinib, have significantly improved disease-free survival in stage ⅠB EGFRm NSCLC according to the seventh edition of the TNM staging system. However, the survival benefits in this population based on the eighth/ninth edition staging systems have yet to be fully validated, and stage ⅠB NSCLC patients exhibit different treatment response patterns. Consequently, current research focuses on high-risk subgroups to optimize treatment outcomes. Major clinical challenges include acquired resistance, determining the optimal treatment timing, and implementing individualized treatment strategies. Future research should concentrate on elucidating the mechanisms of resistance, optimizing treatment timing, establishing precise risk stratification systems, and exploring personalized treatment strategies guided by dynamic monitoring of circulating tumor DNA. This review aims to provide a comprehensive analysis of these key issues and offer a theoretical foundation for optimizing the clinical practice of adjuvant targeted therapy in stage ⅠB NSCLC.
5.Application and development direction of finite element method in biomechanical analysis of thoracolumbar fractures of the spine
Kai HE ; Wenhua XING ; Feng LI ; Shengxiang LIU ; Xianming BAI ; Chen ZHOU ; Xu GAO ; Yu QIAO ; Qiang HE ; Zhiyu GAO ; Zhen GUO ; Aruhan BAO ; Chade LI
Chinese Journal of Tissue Engineering Research 2025;29(15):3244-3252
BACKGROUND:The highest incidence of spinal fracture is in the thoracolumbar segment,and its symptoms are back pain,posterior convexity deformity,activity limitation,or with spinal cord nerve injury causing lower limb pain,numbness,and even paraplegia and other complications.The finite element method is a digital computer modeling technique,which can simulate the physical model and carry out force analysis realistically.OBJECTIVE:To review the application of finite element method in thoracolumbar spine fractures.METHODS:We searched the Chinese and English literature databases PubMed,Web of Science,and CNKI for relevant literature on the application of the finite element analysis method in spinal thoracolumbar fracture published before March 2024.The search terms in Chinese and English were:finite element analysis methods,biomechanical phenomena,stress analysis,thoracolumbar fractures,spinal fractures.Finally,55 papers were included.RESULTS AND CONCLUSION:(1)The exploration of thoracolumbar fractures caused by different etiologies(osteoporotic,traumatic,and pathological)through the finite element method is conducive to a deeper understanding of the biomechanics of various types of thoracolumbar fractures,and to improve the individualized and fine-tuned treatment of thoracolumbar fractures.(2)The finite element analysis of a single sample or a small number of samples has the chance,and a larger number of samples are required for the future finite element analysis to reduce the chance caused by the sample.(3)The rigid structure of bones alone cannot meet the biomechanical working conditions of the integrity of the physical object,and future finite element models need to incorporate all the structures of the physical object(e.g.,soft tissues,such as muscles and ligaments)as far as possible.(4)The finite element method has been used in more studies on osteoporotic and traumatic thoracolumbar spine fractures,which will need to be more in-depth in the future,and less in the field of pathologic thoracolumbar fractures,which has a wider scope for future research.
6.Recent Advances in the Treatment of Non-small Cell Lung Cancer with Brigatinib.
Chinese Journal of Lung Cancer 2025;28(6):450-459
The discovery of anaplastic lymphoma kinase (ALK) tyrosine kinase gene rearrangement mutations in non-small cell lung cancer (NSCLC) has driven continuous advancements in ALK-targeted therapies. The next generation of ALK tyrosine kinase inhibitor, Brigatinib, has demonstrated significant efficacy in patients with ALK-positive NSCLC, offering clinical benefits in deep response of tumor, treatment of brain metastases patients, quality of life, and long-term survival. This review will provide current advancements and exploratory directions for Brigatinib.
.
Humans
;
Carcinoma, Non-Small-Cell Lung/enzymology*
;
Lung Neoplasms/enzymology*
;
Pyrimidines/therapeutic use*
;
Organophosphorus Compounds/therapeutic use*
;
Antineoplastic Agents/therapeutic use*
;
Protein Kinase Inhibitors/therapeutic use*
7.Application and development direction of finite element method in biomechanical analysis of thoracolumbar fractures of the spine
Kai HE ; Wenhua XING ; Feng LI ; Shengxiang LIU ; Xianming BAI ; Chen ZHOU ; Xu GAO ; Yu QIAO ; Qiang HE ; Zhiyu GAO ; Zhen GUO ; Aruhan BAO ; Chade LI
Chinese Journal of Tissue Engineering Research 2025;29(15):3244-3252
BACKGROUND:The highest incidence of spinal fracture is in the thoracolumbar segment,and its symptoms are back pain,posterior convexity deformity,activity limitation,or with spinal cord nerve injury causing lower limb pain,numbness,and even paraplegia and other complications.The finite element method is a digital computer modeling technique,which can simulate the physical model and carry out force analysis realistically.OBJECTIVE:To review the application of finite element method in thoracolumbar spine fractures.METHODS:We searched the Chinese and English literature databases PubMed,Web of Science,and CNKI for relevant literature on the application of the finite element analysis method in spinal thoracolumbar fracture published before March 2024.The search terms in Chinese and English were:finite element analysis methods,biomechanical phenomena,stress analysis,thoracolumbar fractures,spinal fractures.Finally,55 papers were included.RESULTS AND CONCLUSION:(1)The exploration of thoracolumbar fractures caused by different etiologies(osteoporotic,traumatic,and pathological)through the finite element method is conducive to a deeper understanding of the biomechanics of various types of thoracolumbar fractures,and to improve the individualized and fine-tuned treatment of thoracolumbar fractures.(2)The finite element analysis of a single sample or a small number of samples has the chance,and a larger number of samples are required for the future finite element analysis to reduce the chance caused by the sample.(3)The rigid structure of bones alone cannot meet the biomechanical working conditions of the integrity of the physical object,and future finite element models need to incorporate all the structures of the physical object(e.g.,soft tissues,such as muscles and ligaments)as far as possible.(4)The finite element method has been used in more studies on osteoporotic and traumatic thoracolumbar spine fractures,which will need to be more in-depth in the future,and less in the field of pathologic thoracolumbar fractures,which has a wider scope for future research.
8.Construction and validation of a prediction model for UGIB in patients receiving dual antiplatelet therapy after PCI
Jingyi YANG ; Bing PAN ; Shengxiang FENG ; Jiexin MING ; Hongwei YU
Chinese Journal of Geriatric Heart Brain and Vessel Diseases 2025;27(5):596-600
Objective To explore the risk factors for UGIB after dual antiplatelet therapy(aspirin+P2Y12 receptor antagonist)in elderly patients with acute coronary syndrome(ACS)undergoing PCI,and then construct a nomogram model.Methods A total of 1590 elderly patients diagnosed with ACS and then undergoing PCI in Jinzhou Central Hospital from January 2019 to June 2022 were retrospectively recruited,and randomly divided into a testing group(n=1114)and a valida-tion group(n=476)in a ratio of 7∶3.Univariate and multivariate logistic regression analyses were applied to identify the independent risk factors for UGIB events,and then a prediction model was constructed and verified for its diagnostic performance.The predictive value of our prediction model for UGIB events was compared with that of PRECISE-DAPT scoring system.Results There were no statistical differences in baseline data between the testing group and the validation group(P>0.05).The incidence of UGIB was 3.9%(62/1590)in the patients.Multivariate logistic regression analysis indicated that age(OR=1.064,95%CI:1.032-1.097,P=0.000),alcohol(OR=2.433,95%CI:1.220-4.823,P=0.011),heart failure(OR=3.734,95%CI:1.882-7.404,P=0.000),gastrointestinal ulcer/bleeding(OR=3.030,95%CI:1.391-6.618,P=0.005),and Cr(OR=1.017,95%CI:1.014-1.040,P=0.000)were independent risk factors for UGIB in these patients after dual antiplatelet therapy.The constructed nomogram model based on the risk factors obtained an AUC value of 0.806(95%CI:0.739-0.872)in the testing set and 0.838(95%CI:0.737-0.945)in the validation set.The AUC value of the PRECISE-DAPT scoring system in predicting UGIB was 0.674(95%CI:0.583-0.766),which was significantly lower than our mod-el(P<0.05),indicating the nonogram showing good discriminability.Calibration curve analysis and H-L goodness of fit test revealed that our model had good consistency and was well fit(vali-dation set:P=0.846,testing set:P=0.326).Decision curve analysis displayed that our model showed good potential clinical benefits.Conclusion Age,history of gastrointestinal ulcer/bleed-ing,alcohol,heart failure and Cr are independent risk factors for UGIB in these post-PCI patients after dual antiplatelet therapy.The prediction model constructed with these factors has good dis-criminability,calibration and fitting,shows sound clinical application,and can be served as an ef-fective prediction tool for UGIB events in the patients.
9.Clinical and genetic analysis of a child with Spondyloocular syndrome due to compound heterozygous variants of XYLT2 gene
Miaomiao CHEN ; Shengxiang HUANG ; Yu TIAN ; Xinghan WU ; Yu ZHENG ; Shuju ZHANG ; Yu PENG ; Hua WANG
Chinese Journal of Medical Genetics 2024;41(11):1316-1322
Objective:To explore the clinical characteristics and genetic etiology of a child with Spondyloocular syndrome (SOS) in order to enhance the awareness and understanding of this disease.Methods:A 3.5-year-old boy with SOS who had presented at the Department of Medical Genetics of Hunan Children′s Hospital on August 10, 2023 due to the repeated fractures for over 2 years and after binocular cataract surgery was selected as the study subject. Clinical data of his pedigree were collected, and peripheral venous blood samples were collected for the extraction of genomic DNA and subjected to trio-whole exome sequencing. Candidate variants were verified by Sanger sequencing and analyzed with bioinformatic software. This study was approved by the Medical Ethics Committee of Hunan Children′s Hospital (No. KYSQ2022-263).Results:The child had manifested repeated fractures, bilateral bowed femur, osteoporosis, cataract, atrial septal defect, and developmental delay. Ultrasonography has revealed fetal edema, peritoneal effusion, pleural effusion and polyhydramnios. Trio-whole exome sequencing and Sanger sequencing revealed that he has harbored compound heterozygous variants of the XYLT2 gene, namely c. 1103_1104delAG (p.Gln368Argfs*8) and c. 1238_1253delinsA (p.Val413_Pro418delinsGlu), which were inherited from his phenotypically normal father and mother, respectively. Neither variant was reported previously. Based on the guidelines from the American College of Medical Genetics and Genomics (ACMG) and recommendations from the Clinical Genome Resource (ClinGen), the c. 1103_1104delAG was predicted as a pathogenic variant (PVS1+ PM2_Supporting+ PP4), whilst the c.1238_1253delinsA was predicted as a likely pathogenic variant (PM4+ PM3+ PM2_Supporting+ PP4). Conclusion:The c. 1103_1104delAG and c. 1238_1253delinsA compound heterozygous variants of the XYLT2 gene probably underlay the pathogenesis in this child. Above finding has enriched the phenotypic and mutational spectrum of SOS, and provided a basis for the clinical diagnosis, treatment, prognosis assessment and genetic counseling for this pedigree.
10.Clinical and genetic analysis of a child with Spondyloocular syndrome due to compound heterozygous variants of XYLT2 gene.
Miaomiao CHEN ; Shengxiang HUANG ; Yu TIAN ; Xinghan WU ; Yu ZHENG ; Shuju ZHANG ; Yu PENG ; Hua WANG
Chinese Journal of Medical Genetics 2024;41(10):1316-1322
OBJECTIVE:
To explore the clinical characteristics and genetic etiology of a child with Spondyloocular syndrome (SOS) in order to enhance the awareness and understanding of this disease.
METHODS:
A 3.5-year-old boy with SOS who had presented at the Department of Medical Genetics of Hunan Children's Hospital on August 10, 2023 due to the repeated fractures for over 2 years and after binocular cataract surgery was selected as the study subject. Clinical data of his pedigree were collected, and peripheral venous blood samples were collected for the extraction of genomic DNA and subjected to trio-whole exome sequencing. Candidate variants were verified by Sanger sequencing and analyzed with bioinformatic software. This study was approved by the Medical Ethics Committee of Hunan Children's Hospital (Ethics No. KYAQ2022-263).
RESULTS:
The child had manifested repeated fractures, bilateral bowed femur, osteoporosis, cataract, atrial septal defect, and developmental delay. Ultrasonography has revealed fetal edema, peritoneal effusion, pleural effusion and polyhydramnios. Trio-whole exome sequencing and Sanger sequencing revealed that he has harbored compound heterozygous variants of the XYLT2 gene, namely c.1103_1104delAG (p.Gln368Argfs*8) and c.1238_1253delinsA (p.Val413_Pro418delinsGlu), which were inherited from his phenotypically normal father and mother, respectively. Neither variant was reported previously. Based on the guidelines from the American College of Medical Genetics and Genomics (ACMG) and recommendations from the Clinical Genome Resource (ClinGen), the c.1103_1104delAG was predicted as a pathogenic variant (PVS1+PM2_Supporting+PP4), whilst the c.1238_1253delinsA was predicted as a likely pathogenic variant (PM4+PM3+PM2_Supporting+PP4).
CONCLUSION
The c.1103_1104delAG and c.1238_1253delinsA compound heterozygous variants of the XYLT2 gene probably underlay the pathogenesis in this child. Above finding has enriched the phenotypic and mutational spectrum of SOS, and provided a basis for the clinical diagnosis, treatment, prognosis assessment and genetic counseling for this pedigree.
Humans
;
Male
;
Child, Preschool
;
Heterozygote
;
Pentosyltransferases/genetics*
;
Pedigree
;
UDP Xylose-Protein Xylosyltransferase
;
Mutation
;
Exome Sequencing
;
Genetic Testing

Result Analysis
Print
Save
E-mail